Mercado global de transplante de células estaminais hematopoiéticas – Tendências do setor e previsão para 2030

Análise e dimensão do mercado de transplante de células estaminais hematopoiéticas

Nos últimos anos, prevê-se que o mercado de transplante de células estaminais hematopoiéticas cresça rapidamente durante o período de previsão. Em 2018, esperava-se que a incidência global de leucemia fosse de 437.033 novos casos e quase 309.006 mortes, de acordo com o estudo GLOBOCAN 2018. De acordo com a Organização Mundial de Saúde (OMS), são realizados mais de 2.000 transplantes de células estaminais hematopoiéticas do sangue do cordão umbilical a cada ano. A medula óssea e o sangue contêm células estaminais hematopoiéticas (HSCs). As células progenitoras hematopoiéticas são outro nome para as mesmas (HPCs). As células estaminais hematopoiéticas podem produzir plaquetas, glóbulos brancos e glóbulos vermelhos, entre outras células sanguíneas. Estas células são utilizadas para reconstruir ou substituir o sistema hematopoiético de um doente no tratamento de perturbações malignas (como o linfoma e a leucemia) e não malignas (incluindo insuficiência da medula óssea e hemoglobinopatias).

A Data Bridge Market Research analisa que o mercado global de transplante de células estaminais hematopoiéticas, que foi de 2.610,91 milhões de dólares em 2022, subiria para 6.327,28 milhões de dólares até 2030, e deverá passar por um CAGR de 11, 7% durante o período de previsão. Isto indica que o valor de mercado. O "(HSCT autólogo" domina o segmento de tipo do mercado global de transplante de células estaminais hematopoiéticas devido à crescente procura por melhores métodos de diagnóstico e tratamento. Para além dos insights sobre os cenários de mercado, tais como o valor de mercado, a taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research incluem também análises aprofundadas de especialistas, epidemiologia de pacientes, análise de pipeline, análise de preços e estrutura regulamentar.

Âmbito e segmentação do mercado de transplante de células estaminais hematopoiéticas

Definição de mercado

O transplante de células estaminais hematopoiéticas (TCTH) é uma opção de tratamento para vários tipos de cancro e outras doenças. As células estaminais do sangue e as células estaminais da medula óssea são fontes de células estaminais. As células sanguíneas jovens ou imaturas presentes na medula óssea são conhecidas como células estaminais hematopoiéticas. Apenas uma pequena percentagem destas células sanguíneas amadurece na medula óssea e chega à corrente sanguínea. As células estaminais do sangue periférico são as células que entram na corrente sanguínea. O transplante de células estaminais hematopoiéticas substitui as células estaminais hematopoiéticas ausentes, doentes ou lesadas por células estaminais hematopoiéticas saudáveis, como resultado de quimioterapia ou radiação.

Dinâmica global do mercado de transplante de células estaminais hematopoiéticas

Motoristas

• Aumento da prevalência de leucemia e linfoma

Estima-se que a crescente prevalência de leucemia e linfoma aumente o crescimento do mercado de transplante de células estaminais hematopoiéticas. De acordo com o relatório de 2019 da Sociedade de Leucemia e Linfoma, 176.200 pessoas nos EUA foram diagnosticadas com leucemia, linfoma ou mieloma, e 1.399.180 pessoas viviam com leucemia linfática e mieloma. A taxa de incidência crescente irá provavelmente alimentar a procura de transplante de células estaminais hematopoiéticas (TCTH), impulsionando o mercado de TCTH.

• Número crescente da população geriátrica

The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to getting hematopoietic stem cell transplantation, further estimated to enhance the market's growth rate

Opportunities

• Advancements in Transplantation Techniques

The field of HSCT continues to evolve, with advancements in transplantation techniques, supportive care, and donor selection strategies. These advancements have improved transplant outcomes, expanded eligibility criteria, and increased the number of patients who can benefit from HSCT. The market can capitalize on these advancements to offer innovative transplantation solutions and expand the patient pool.

• Increasing Adoption of Autologous HSCT

Autologous HSCT involves using a patient's stem cells, often collected and stored prior to high-dose chemotherapy or radiation therapy. The demand for autologous HSCT is increasing due to its potential benefits, such as reduced risk of GVHD and improved survival rates. This trend presents an opportunity for market players to expand their offerings and develop innovative solutions specifically tailored to autologous HSCT

• Growing Medical Tourism

Medical tourism, where patients travel to other countries for medical treatments, including HSCT, is on the rise. Factors such as cost advantages, availability of specialized centers, and shorter waiting times in certain regions attract patients seeking HSCT. This presents an opportunity for market players to cater to international patients and collaborate with medical tourism facilitators.

Restraints/Challenges

• Limited Availability of Suitable Donors

HSCT requires a suitable donor match for successful transplantation. However, finding a suitable donor, especially for allogeneic transplantation, can be challenging due to the need for human leukocyte antigen (HLA) compatibility. The limited availability of suitable donors can restrict the number of patients who can undergo HSCT.

• Transplant-Related Morbidity and Mortality

HSCT carries a risk of complications, including graft failure, graft-versus-host disease (GVHD), infections, organ toxicity, and relapse. These complications can lead to significant morbidity and even mortality. The risk of these adverse events can deter both patients and healthcare providers from considering HSCT as a treatment option, particularly for older or medically fragile patients.

• Lack of Standardization

HSCT involves a complex process with various steps and components, including stem cell collection, conditioning regimens, and post-transplant care. The lack of standardization in protocols, procedures, and supportive care practices can lead to variability in outcomes and hinder the widespread adoption of HSCT.

• Long-Term Follow-up and Survivorship Care

HSCT survivors require long-term follow-up care, including monitoring for late effects, managing chronic graft-versus-host disease (GVHD), and addressing psychosocial and quality-of-life issues. The provision of comprehensive survivorship care can be challenging due to limited resources, coordination of multidisciplinary care, and addressing the unique needs of HSCT survivors.

This hematopoietic stem cell transplantation market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hematopoietic stem cell transplantation market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth

Recent Developments

• In August 2021, Magenta Biosciences, announced a spin-off collaboration with bluebird bio to develop HSPC-based gene therapies for genetic diseases. The specific date of this announcement is not provided.
• In July 2020, Gamida Cell announced positive results from a Phase 3 clinical trial of NiCord, an investigational product. The trial showed improved overall survival and reduced time to neutrophil engraftment compared to standard umbilical cord blood transplantation.

This global hematopoietic stem cell transplantation market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global hematopoietic stem cell transplantation market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Hematopoietic Stem Cell Transplantation Market Scope

The global hematopoietic stem cell transplantation market is categorized into five notable segments, which are based on the basis of product, sample, mode of purchase, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Allogeneic HSCT
• Autologous HSCT
• Others

 Indication

• Congenital Metabolic Defects
• Hemoglobinopathies
• Myelodysplastic Syndrome
• Myeloproliferative Syndromes
• Multiple Sclerosis
• Lymphoma
• Immune-Deficiency Illnesses
• Others

Application

• Bone Marrow Stem Cells
• Peripheral Blood Stem Cells
• Umbilical Cord Stem Cells
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Hematopoietic Stem Cell Transplantation Market Regional Analysis/Insights

The global hematopoietic stem cell transplantation market is analysed and market size insights and trends are provided by country, type, indication, application, end-users and distribution channel as referenced above.

The countries covered in the hematopoietic stem cell transplantation market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America.

North America dominates the hematopoietic stem cell transplantation market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of patients.

Asia-Pacific is expected to witness significant growth during the forecast period from 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for skin care, the large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.

Cenário competitivo e análise global da quota de mercado de transplante de células estaminais hematopoéticas

O panorama competitivo do mercado global de transplante de células estaminais hematopoiéticas fornece detalhes dos concorrentes. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produtos, largura e amplitude do produto, domínio da aplicação. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado global de transplante de células estaminais hematopoiéticas

Alguns dos principais players que operam no mercado global de transplante de células estaminais hematopoiéticas são:

• Otsuka America Pharmaceutical, Inc.
• Akari Therapeutics, Plc (EUA)
• Merck KGaA (Alemanha)
• Takeda Pharmaceutical Company Limited (Japão)
• Lonza (Suíça)
• GlaxoSmithKline plc (Reino Unido)
• Novartis AG (Suíça)
• Merck & Co., Inc.
• (EUA)
• Sanofi (França)
• FUJIFILM Holdings Corporation (Japão)
• bluebird bio, Inc.
• Pluristem Therapeutics Inc.
• (EUA)
• Kiadis Pharma (Holanda)
• Taiga Biotechnologies, Inc.
• CellGenix GmbH (Alemanha)
• Escape Therapeutics, Inc.
• Marker Therapeutics, Inc.
• Talaris Therapeutics (EUA)

SKU-53864